Treating COPD with PDE 4 inhibitors

References

• AdamsSGMeloJLutherM2001Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPDChest117134552
   Web of Science ®Google Scholar
• AdcockIMChungKFCaramoriG2006Kinase inhibitors and airway inflammationEur J Pharmacol5331183216469308
   PubMed Web of Science ®Google Scholar
• AdcockIMItoKBarnesPJ2005Histone deacetylation: an important mechanism in inflammatory lung diseasesCOPD24455517147010
   PubMedGoogle Scholar
• AlvesACPiresALACruzHN1996Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitroEur J Pharmacol31289968891583
   PubMed Web of Science ®Google Scholar
• American Thoracic Society1995Standards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAm J Resp Crit Care Med152S771207582322
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEMurrayRP2002Smoking and lung function of Lung Health Study participants after 11 yearsAm J Respir Crit Care Med166675912204864
   PubMed Web of Science ®Google Scholar
• AnthonisenNRManfredaJWarrenCP1987Antibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med1061962043492164
   PubMed Web of Science ®Google Scholar
• AntoniuSA2006aHistone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary diseaseExpert Opin Ther Targets103293216548780
   PubMed Web of Science ®Google Scholar
• AntoniuSA2006bRoflumilast for the treatment of chronic obstructive pulmonary diseaseCurr Opin Investig Drugs741217
   PubMed Web of Science ®Google Scholar
• AppletonSJonesTPooleP2006Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev19CD006101
   Google Scholar
• AshtonMJCookDCFentonG1994Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analoguesJ Med Chem3716967038201604
   PubMed Web of Science ®Google Scholar
• AustinMWood-BakerR2006Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary diseaseCochrane Database Syst Rev19CD005534
   Google Scholar
• BannerKHTrevethickMA2004PDE4 inhibition: a novel approach for the treatment of inflammatory bowel diseaseTrends Pharmacol Sci25430615276712
   PubMed Web of Science ®Google Scholar
• BarnesCJChungKFPageCP1988Inflammatory mediators and asthmaPharmacol Rev4049843064106
   PubMed Web of Science ®Google Scholar
• BarnesPJ1995Molecular mechanisms of antiasthma therapyAnn Med2753158541027
   PubMed Web of Science ®Google Scholar
• BarnesPJ1998New therapies for chronic obstructive pulmonary diseaseThorax53137479624300
   PubMed Web of Science ®Google Scholar
• BarnesPJ2000Chronic obstructive pulmonary diseaseN Engl J Med3432698010911010
   PubMed Web of Science ®Google Scholar
• BarnesPJ2003Theophylline: new perspectives for an old drugAm J Respir Crit Care Med678131812623857
   PubMed Web of Science ®Google Scholar
• BarnesPJ2006aNovel signal transduction modulators for the treatment of airway diseasesPharmacol Ther1092384516171872
   PubMed Web of Science ®Google Scholar
• BarnesPJ2006bReduced histone deacetylase in COPD: clinical implicationsChest129151516424426
   PubMed Web of Science ®Google Scholar
• BarnetteMSBartusJOBurmanM1996Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram bindingBiochem Pharmacol51949568651945
   PubMed Web of Science ®Google Scholar
• BarnetteMSChristensenSBEssayanDM1998SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actionsJ Pharmacol Exp Ther28442069435206
   PubMed Web of Science ®Google Scholar
• BarnetteMSChristensenSBUnderwoodDC1996Phosphodiesterase 4: Biological underpinnings for the design improved inhibitorsPharmacol Rev Commun86573
   Google Scholar
• BarnetteMSGrousMCieslinskiLB1995Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding siteJ Pharmacol Exp Ther27313964027791113
   PubMed Web of Science ®Google Scholar
• BarnetteMSUnderwoodDC2000New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung diseaseCurr Opin Pulmon Med61649
   PubMedGoogle Scholar
• BarnetteMS1999Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)Prog Drug Res5319322910616299
   PubMedGoogle Scholar
• BarrRGRoweBHCamargoCAJr2003Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trialsBrit Med J327643814500434
   PubMed Web of Science ®Google Scholar
• BatemanEDIzquierdoJLHarnestU2006Efficacy and safety of roflumilast in the treatment of asthmaAnn Allergy Asthma Immunol966798616729780
   PubMed Web of Science ®Google Scholar
• BeavoJAContiMHeaslipRJ1994Multiple cyclic nucleotide phosphodiesterasesMol Pharmacol463994057935318
   PubMed Web of Science ®Google Scholar
• BelleguicCCorbelMGermainN2000Reduction of matrix metalloproteinase-9 activity by the selective phosphodiesterase 4 inhibitor, RP 73–401 in sensitized miceEur J Pharmacol4043697310996602
   PubMed Web of Science ®Google Scholar
• BenderATBeavoJA2006Cyclic nucleotide phosphodiesterases: molecular regulation to clinical usePharmacol Rev5848852016968949
   PubMed Web of Science ®Google Scholar
• BianHZhangJWuP2004Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humansBiochem Pharmacol6822293615498513
   PubMed Web of Science ®Google Scholar
• BlanchardAR2002Treatment of COPD exacerbations: pharmacologic options and modification of risk factorsPostgrad Med111657512082921
   PubMed Web of Science ®Google Scholar
• BolgerGBErdoganSJonesRE1997Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D geneBiochem J328539489371713
   PubMed Web of Science ®Google Scholar
• BolgerGB1994Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymesCell Signalling685197718405
   PubMed Web of Science ®Google Scholar
• BonneauOWyssDFerrettiS2006Effect of adenosine A2A receptor activation in murine models of respiratory disordersAm J Physiol Lung Cell Mol Physiol290L10364316339780
   PubMed Web of Science ®Google Scholar
• BorronWdeBoisblancBP1998Steroid therapy for chronic obstructive pulmonary diseaseCurr Opin Pulmon Med4615
   PubMedGoogle Scholar
• Boswell-SmithVCazzolaMPageCP2006Are phosphodiesterase 4 inhibitors just more theophylline?J Allergy Clin Immunol11712374316750981
   PubMed Web of Science ®Google Scholar
• Boswell-SmithVPageCP2006Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory diseaseExpert Opin Investig Drugs15110513
   PubMed Web of Science ®Google Scholar
• Boswell-SmithVSpinaDPageCP2006Phosphodiesterase inhibitorsBr J Pharmacol147Suppl 1S252716402111
   PubMed Web of Science ®Google Scholar
• BousquetJAubierMSastreJ2006Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthmaAllergy6172816364159
   PubMed Web of Science ®Google Scholar
• BowlerRPBarnesPJCrapoJD2004The role of oxidative stress in chronic obstructive pulmonary diseaseCOPD12557717136992
   PubMedGoogle Scholar
• BrigantiASaloniaAGallinaA2005Oral phosphodiesterase type 5 inhibitors for erectile dysfunctionNat Clin Pract Urol22394716474835
   PubMedGoogle Scholar
• BruijnzeelPL1989Contribution of eosinophil derived mediators in asthmaIntl Arch Allergy Appl Immunol90Suppl 15763
   PubMedGoogle Scholar
• BrysonSERodgerIW1987Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolated airway smooth muscleBr J Pharmacol92673812447991
   PubMed Web of Science ®Google Scholar
• BuhlRFarmerSG2004Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthmaProc Am Thorac Soc11364216113426
   PubMedGoogle Scholar
• BuhlRFarmerSG2005Future directions in the pharmacologic therapy of chronic obstructive pulmonary diseaseProc Am Thorac Soc2839316113474
   PubMedGoogle Scholar
• BurgessJKOliverBGPonirisMH2006A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitroJ Allergy Clin Immunol1186495716950284
   PubMed Web of Science ®Google Scholar
• BurnoufCAuclairEAvenelN2000Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydrol[1,4]diazepino[6,7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitorsJ Med Chem4348506711123995
   PubMed Web of Science ®Google Scholar
• BushnikTContiM1996Role of multiple cAMP-specific phosphodiesterase variantsBiochem Soc Trans241014198968503
   PubMed Web of Science ®Google Scholar
• CaramoriGAdcockIMItoK2004Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPDCurr Opin Investig Drugs511417
   PubMedGoogle Scholar
• CardGLEnglandBPSuzukiY2004Structural basis for the activity of drugs that inhibit phosphodiesterasesStructure1222334715576036
   PubMed Web of Science ®Google Scholar
• CavallaDFrithR1995Phosphodiesterase IV inhibitors: structural diversity and therapeutic potential in asthmaCurr Med Chem256172
   Web of Science ®Google Scholar
• ChambersRJMarfatAChengJB1997Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor-alphaBioorg Med Chem Lett773944
   Web of Science ®Google Scholar
• ChristensenSBGuiderAForsterCJ19981,4-cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthmaJ Med Chem41821359526558
   PubMed Web of Science ®Google Scholar
• ChristieP2005Roflumilast: a selective phosphodiesterase 4 inhibitorDrugs Today416677516389409
   PubMed Web of Science ®Google Scholar
• ChungKF2006Cytokines as targets in chronic obstructive pulmonary diseaseCurr Drug Targets76758116787167
   PubMed Web of Science ®Google Scholar
• ComptonCHGubbJNiemanR2001Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging studyLancet3582657011498212
   PubMed Web of Science ®Google Scholar
• ConnorsAFJrDawsonNVThomasC1996Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)Am J Resp Crit Care Med154959678887592
   PubMed Web of Science ®Google Scholar
• ContiMJinSL1999The molecular biology of cyclic nucleotide phosphodiesterasesProg Nucleic Acid Res Mol Biol6313810506827
   PubMed Web of Science ®Google Scholar
• CorbelMBelleguicCBoichotE2002Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosisCell Biol Tox185161
   PubMed Web of Science ®Google Scholar
• CorbelMGermainNLanchouJ2002The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between tumor necrosis factor-alpha and interleukin-10J Pharmacol Exp Ther3012586511907182
   PubMed Web of Science ®Google Scholar
• CortijoJBouJBeletaJ1993Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchusBr J Pharmacol10856288383567
   PubMed Web of Science ®Google Scholar
• CostelloJ1998Cardiac effects of beta-agonists in patents with COPD (chronic obstructive pulmonary disease)Chest11435349726710
   PubMed Web of Science ®Google Scholar
• CowanC2005Roflumilast for asthma and chronic obstructive pulmonary diseaseIssues Emerg Health Technol741416317827
   PubMedGoogle Scholar
• CrockerICTownleyRG1999Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseasesDrugs Today355193512973397
   PubMed Web of Science ®Google Scholar
• CrouchE1990Pathobiology of pulmonary fibrosisAm J Lung Cell Mol Physiol259L15984
   PubMed Web of Science ®Google Scholar
• D’AlonzoGE1996Theophylline revisitedAllergy Asthma Proc1733598993727
   PubMed Web of Science ®Google Scholar
• DanielPBWalkerWHHabenerJF1998Cyclic AMP signaling and gene regulationAnn Rev Nutr18353839706229
   PubMed Web of Science ®Google Scholar
• De BritoFBSounessJEWarnePJ1997Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory diseaseEmerging Drugs224968
   Google Scholar
• de GaravillaLGrecoMNSukumarN2005A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivoJ Biol Chem28018001715741158
   PubMed Web of Science ®Google Scholar
• DeKorteCJ2003Current and emerging therapies for the management of chronic inflammation in asthmaAm J Health Syst Pharm6019495914531240
   PubMed Web of Science ®Google Scholar
• DengYMXieQMTangHF2006Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthmaEur J Pharmacol5471253516956605
   PubMed Web of Science ®Google Scholar
• DentGGiembyczMA1995Selective phosphodiesterase inhibitors in the therapy of asthmaClin Immunother342337
   Google Scholar
• DentGGiembyczMA1996Phosphodiesterase inhibitors: Lily the Pink’s medicinal compound for asthma?Thorax5164798693451
   PubMed Web of Science ®Google Scholar
• DewanNARafiqueSKanwarB2000Acute exacerbation of COPD: factors associated with poor treatment outcomeChest1176627110712989
   PubMed Web of Science ®Google Scholar
• DohertyDEBriggsDDJr2004Long-term pharmacologic management of patients with chronic obstructive pulmonary diseaseClin CornerstoneSuppl 2S293415500181
   PubMedGoogle Scholar
• DomejWFoldes-PappZFlogelE2006Chronic obstructive pulmonary disease and oxidative stressCurr Pharm Biotechnol71172316724946
   PubMed Web of Science ®Google Scholar
• DonnellyLERogersDF2003Therapy for chronic obstructive pulmonary disease in the 21st centuryDrugs6319739812962514
   PubMed Web of Science ®Google Scholar
• D’SouzaAOSmithMJMillerLA2006An appraisal of pharmacoeconomic evidence of maintenance therapy for COPDChest129169370816778291
   PubMed Web of Science ®Google Scholar
• DykeHJMontanaJG2002Update on the therapeutic potential of PDE4 inhibitorsExpert Opin Investig Drug11113
   PubMed Web of Science ®Google Scholar
• ErdoganSHouslayMD1997Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variantBiochem J321165759003416
   PubMed Web of Science ®Google Scholar
• EzeamuzieCI2001Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitorsEur J Pharmacol417111811301054
   PubMed Web of Science ®Google Scholar
• FabbriLMHurdSS2003Global strategy for the diagnosis, management and prevention of COPD: 2003 updateEur Respir J221212882441
   PubMed Web of Science ®Google Scholar
• Fan ChungK2006Phosphodiesterase inhibitors in airways diseaseEur J Pharmacol5331101716458289
   PubMed Web of Science ®Google Scholar
• GambleEGrootendorstDCBrightlingCE2003Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1689768212816740
   PubMed Web of Science ®Google Scholar
• GartlehnerGHansenRACarsonSS2006Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomesAnn Fam Med42536216735528
   PubMed Web of Science ®Google Scholar
• GeorgitisJW1999The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthmaChest115210179925086
   PubMed Web of Science ®Google Scholar
• GhavamiAHirstWDNovakTJ2006Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?Drugs R D7637116542053
   PubMedGoogle Scholar
• GibsonLCHastingsSFMcPheeI2006The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme familyEur J Pharmacol538394216674936
   PubMed Web of Science ®Google Scholar
• GiembyczMADentG1992Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthmaClin Exp Allergy22337441316796
   PubMed Web of Science ®Google Scholar
• GiembyczMA2000Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?Drugs5919321210730545
   PubMed Web of Science ®Google Scholar
• GiembyczMA2001Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary diseaseExpert Opin Invest Drugs10136179
   PubMed Web of Science ®Google Scholar
• GiembyczMA2002Development status of second generation PDE4 inhibitors for asthma and COPD: the story so farMonaldi Arch Chest Dis57486412174704
   PubMedGoogle Scholar
• GiembyczMA2005aPhosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary diseaseProc Am Thorac Soc23263316267357
   PubMedGoogle Scholar
• GiembyczMA2005bLife after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitorsCurr Opin Pharmacol52384415907909
   PubMed Web of Science ®Google Scholar
• GiembyczMA2006An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary diseaseBr J Clin Pharmacol621385216842388
   PubMed Web of Science ®Google Scholar
• [GOLD] Global Initiative for Chronic Obstructive Lung Disease2003Executive summary (updated 2003). Accessed May 28, 2007. URL: http://www.goldcopd.com
   Google Scholar
• Gonçalves de MoraesVLSingerMVargaftigBB1998Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lungBr J Pharmacol12363169517381
   PubMed Web of Science ®Google Scholar
• GriswoldDEWebbEFBadgerAM1998SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduced tumor necrosis factor alpha and interlukin-4 production in vivoJ Pharmacol Exp Ther287705119808700
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSABaanR2003Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary diseasePulmon Pharmacol Ther1611520
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSABenschopN2003Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)Pulm Pharmacol Ther16341714580925
   PubMed Web of Science ®Google Scholar
• GrowcottEJSpinkKGRenX2006Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cellsRespir Res7916423283
   PubMed Web of Science ®Google Scholar
• GuedersMMFoidartJMNoelA2006Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseasesEur J Pharmacol5331334416487964
   PubMed Web of Science ®Google Scholar
• GuerraS2005Overlap of asthma and chronic obstructive pulmonary diseaseCurr Opin Pulmon Med11713
   PubMed Web of Science ®Google Scholar
• GutkeHJGuseJHKhobzaouiM2005AWD-12-281 (inhaled) (elbion/GlaxoSmithKline)Curr Opin Investig Drugs6114958
   PubMedGoogle Scholar
• HantaIKocabasACanacankatanN2006Oxidant-antioxidant balance in patients with COPDLung18451516622773
   PubMed Web of Science ®Google Scholar
• HardakerELBaconAMCarlsonK2004Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary diseaseFASEB J18191314597565
   PubMed Web of Science ®Google Scholar
• HatzelmannASchudtC2001Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitroJ Pharmacol Exp Ther2972677911259554
   PubMed Web of Science ®Google Scholar
• HaunsBHermannRHunnemeyerA2006Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjectsJ Clin Pharmacol4611465316988203
   PubMed Web of Science ®Google Scholar
• HayDWP2000Chronic obstructive pulmonary disease: emerging therapiesCurr Opin Chem Biol44121910959769
   PubMed Web of Science ®Google Scholar
• HolgateSTTwentymanOPRaffertyP1987Primary and secondary effector cells in the pathogenesis of bronchial asthmaIntl Arch Allergy Appl Immunol82498506
   PubMedGoogle Scholar
• HortonYMSullivanMHouslayMD1995Molecular cloning of a novel splice variant of human type IVa (PDE-IVa) cyclic AMP phosphodiesterase and localization of the gene to the p13.1-q12 region of human chromosome 19Biochem J308683917772058
   PubMed Web of Science ®Google Scholar
• HouslayMDAdamsDR2003PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationBiochem J37011812444918
   PubMed Web of Science ®Google Scholar
• HouslayMDSullivanMBolgerGB1998The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actionsAdv Pharmacol442253429547887
   PubMedGoogle Scholar
• HuangZDucharmeYMacdonaldD2001The next generation of PDE4 inhibitorsCurr Opin Chem Biol5432811470607
   PubMed Web of Science ®Google Scholar
• HuangZLiuSZhangL2006Preferential inhibition of human phosphodiesterase 4 by ibudilastLife Sci782663816313925
   PubMed Web of Science ®Google Scholar
• HuangZManciniJA2006Phosphodiesterase 4 inhibitors for the treatment of asthma and COPDCurr Med Chem13325356217168849
   PubMed Web of Science ®Google Scholar
• HustonEHouslayTMBaillieGS2006cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signallingBiochem Soc Trans34504916856845
   PubMed Web of Science ®Google Scholar
• ItoKYamamuraSEssilfie-QuayeS2006Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppressionJ Exp Med20371316380507
   PubMed Web of Science ®Google Scholar
• JacobCLeportMSzilagyiC2002DMSO-treated HL60 cells: a model of neutrophil-like cells mainly expressing PDE4B subtypeIntl Immunopharmacol2164756
   PubMed Web of Science ®Google Scholar
• JacobitzSMcLaughlinMMLiviGP1996Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram bindingMol Pharmacol5089198863835
   PubMed Web of Science ®Google Scholar
• JefferyP2005Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPDPulmon Pharmacol Therapeut18917
   PubMed Web of Science ®Google Scholar
• JefferyPK2001Remodeling in asthma and chronic obstructive lung diseaseAm J Respir Care Med164S2838
   PubMed Web of Science ®Google Scholar
• JinSLBushnikTLanL1998Subcellular localization of rolipramsensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D geneJ Biol Chem2731967289677395
   PubMed Web of Science ®Google Scholar
• JonesNABoswell-SmithVLeverR2005The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitroPulm Pharmacol Ther189310115649851
   PubMed Web of Science ®Google Scholar
• KarishSBGagnonJM2006The potential role of roflumilast: the new phosphodiesterase-4 inhibitorAnn Pharmacother40109610416735669
   PubMed Web of Science ®Google Scholar
• KarlssonJ AAldousD1997Phosphodiesterase 4 inhibitors for the treatment of asthmaCurr Opin Ther Patents79891003
   Web of Science ®Google Scholar
• KeH2004Implications of PDE4 structure on inhibitor selectivity across PDE familiesInt J Impot Res16Suppl 1S24715224132
   PubMed Web of Science ®Google Scholar
• KellermanDJ2002P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearanceChest1215 Suppl201S205S12010852
   PubMed Web of Science ®Google Scholar
• KellyJJBarnesPJGiembyczMA1996Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitorsBiochem J318425368809029
   PubMed Web of Science ®Google Scholar
• KerstjensHATimensW2003Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?Am J Respir Crit Care Med1689141514555456
   PubMed Web of Science ®Google Scholar
• KirkhamPRahmanI2006Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategyPharmacol Ther1114769416458359
   PubMed Web of Science ®Google Scholar
• KnightD2004Talniflumate (Genaera)Curr Opin Investig Drugs555762
   PubMedGoogle Scholar
• KohyamaTLiuXZhuYK2002Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastaseAm J Resp Cell Mol Biol2748794
   PubMed Web of Science ®Google Scholar
• KotlikoffMIKammKE1996Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscleAnn Rev Physiol58115418815788
   PubMed Web of Science ®Google Scholar
• KussHHoefgenNJohanssenS2003In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administrationJ Pharmacol Exp Ther3073738512944497
   PubMed Web of Science ®Google Scholar
• KwakHJSongJSNoZS2005The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxideInflamm Res545081316389572
   PubMed Web of Science ®Google Scholar
• LagenteVMartin-ChoulyCBoichotE2005Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseasesMem Inst Oswaldo Cruz100Suppl 11316
   PubMed Web of Science ®Google Scholar
• LagenteVMoodleyIPerrinS1994Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lungEur J Pharmacol25525368026552
   PubMed Web of Science ®Google Scholar
• LagenteVPruniauxMPJunienJL1995Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitorsAm J Respir Crit Care Med151172047539326
   PubMed Web of Science ®Google Scholar
• LarsonJLPinoMVGeigerLE1996The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in ratsPharmacol Toxicol784498685086
   PubMedGoogle Scholar
• LernerAEpsteinPM2006Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignanciesBiochem J393214116336197
   PubMed Web of Science ®Google Scholar
• LipworthBJ2005Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary diseaseLancet3651677515639300
   PubMed Web of Science ®Google Scholar
• LiuSVeilleuxAZhangL2005Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitorsJ Pharmacol Exp Ther3148465415901792
   PubMed Web of Science ®Google Scholar
• LobbanMShakurYBeattieJ1994Identification of two splice varient forms of type IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brains; selective localization in membrane and cytosolic compartments and differential expression in various brain regionsBiochem J3043994067998974
   PubMed Web of Science ®Google Scholar
• LombardoLJ1995Phosphodiesterase-IV inhibitors: novel therapeutics for the treatment of inflammatory diseasesCurr Pharmaceut. Design125568
   Google Scholar
• LoweJAIIIChengJB1992The PDE IV family of calcium-independent phosphodiesterase enzymesDrugs Fut17799807
   Google Scholar
• MacNeeW2005aPathogenesis of chronic obstructive pulmonary diseaseProc Am Thorac Soc22586616267346
   PubMedGoogle Scholar
• MacNeeW2005bPulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary diseaseProc Am Thorac Soc2506016113469
   PubMedGoogle Scholar
• MadisonJMIrwinRS1998Chronic obstructive pulmonary diseaseLancet352467739708769
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
   PubMed Web of Science ®Google Scholar
• MalhotraSManSFSinDD2006Emerging drugs for the treatment of chronic obstructive pulmonary diseaseExpert Opin Emerg Drugs112759116634702
   PubMedGoogle Scholar
• ManciniGBEtminanMZhangB2006Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary diseaseJ Am Coll Cardiol4725546016781387
   PubMed Web of Science ®Google Scholar
• ManganielloVCMurataTTairaM1995Diversity in cyclic nucleotide phosphodiesterase isoenzyme familiesArch Biochem Biophys3221137574662
   PubMed Web of Science ®Google Scholar
• ManningCDBurmanMChristensenSB1999Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4BBr J Pharmacol1281393810602317
   PubMed Web of Science ®Google Scholar
• MartinCGoggelRDal PiazV2002Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding siteNaunyn Schmiedebergs Arch Pharmacol365284911919652
   PubMed Web of Science ®Google Scholar
• MartinNReidPT2006The potential role of phosphodiesterase inhibitors in the management of asthmaTreat Respir Med52071716696590
   PubMedGoogle Scholar
• MartinaSDIsmailMSVestaKS2006Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary diseaseAnn Pharmacother401822816985092
   PubMed Web of Science ®Google Scholar
• Martin-ChoulyCAAstierAJacobC2004Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitorsLife Sci758234015183075
   PubMed Web of Science ®Google Scholar
• MataMSarriaBBuenestadoA2005Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cellsThorax601445215681504
   PubMed Web of Science ®Google Scholar
• MatsumotoTKobayashiTKamataK2003Phosphodiesterases in the vascular systemJ Smooth Mus Res396786
   PubMedGoogle Scholar
• MatsuyamaWMitsuyamaHWatanabeM2005Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPDChest12838172716354850
   PubMed Web of Science ®Google Scholar
• McEvoyCENiewoehnerDE1998Adverse effects of corticosteroid therapy for COPD: a critical reviewChest11173243
   Web of Science ®Google Scholar
• MehatsCJinSLWahlstromJ2003PDE4D plays a critical role in the control of airway smooth muscle contractionFASEB J1718314114519662
   PubMed Web of Science ®Google Scholar
• MercerPFShuteJKBhowmikA2005MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbationRespir Res22151
   Web of Science ®Google Scholar
• Miller-LarssonASelroosO2006Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonistsCurr Pharm Des1232617917020533
   PubMed Web of Science ®Google Scholar
• MiravitllesMAlvarez-SalaJLLamarcaR2002Treatment and quality of life in patients with chronic obstructive pulmonary diseaseQual Life Res113293812086118
   PubMed Web of Science ®Google Scholar
• MohanAPremanandRReddyLN2006Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unitBMC Pulm Med62717177991
   PubMedGoogle Scholar
• MontminyM1997Transcriptional regulation by cyclic AMPAnn Rev Biochem66807229242925
   PubMed Web of Science ®Google Scholar
• MullerTEngelsPFozardJR1996Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibitionTrends Pharmacol Sci1729488810876
   PubMed Web of Science ®Google Scholar
• MurphyTFSethiSNiedermanMS2000The role of bacteria in exacerbations of COPD: a constructive viewChest118204910893380
   PubMed Web of Science ®Google Scholar
• MurphyTF2006The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary diseaseCurr Opin Infect Dis192253016645482
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezAD1997Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet34914985049167458
   PubMed Web of Science ®Google Scholar
• NassrNLahuGvon RichterO2006Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjectsBr J Clin Pharmacol929
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics2002NCHS data on chronic obstructive pulmonary disorder [online]. Accessed May 28, 2007. URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5106a1.htm
   Google Scholar
• NicholsonCDChallissRAShahidM1991Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymesTrends Pharmacol Sci1219271848733
   PubMed Web of Science ®Google Scholar
• NicholsonCDShahidMBruinJ1995Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthmaJ Pharmacol Exp Ther274678877636728
   PubMed Web of Science ®Google Scholar
• NicholsonCDShahidM1994Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes: their potential utility in the therapy of asthmaPulmon Pharmacol7117
   PubMedGoogle Scholar
• NormanP1999PDE4 inhibitorsCurr Opin Ther Patents9110118
   Web of Science ®Google Scholar
• NormanP2000PDE4 inhibitors: sustained patenting activity as leading drugs near the marketCurr Opin Ther Patents10141527
   Web of Science ®Google Scholar
• ObernolteRRatzliffJBaeckerPA1997Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testisBiochim Biophys Acta1353287979349724
   PubMed Web of Science ®Google Scholar
• O’DonnellRBreenDWilsonS2006Inflammatory cells in the airways in COPDThorax614485416648353
   PubMed Web of Science ®Google Scholar
• OgerSMehatsCBarnetteMS2004Anti-inflammatory and uterorelaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitorsBiol Reprod704586414561639
   PubMed Web of Science ®Google Scholar
• OhbayashiH2002Neutrophil elastase inhibitors as treatment for COPDExpert Opin Investig Drugs1196580
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyTCAnsariTWBarnesNC1997Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1Am J Respir Crit Care Med15585279117016
   PubMed Web of Science ®Google Scholar
• OuaguedMMartin-ChoulyCABrinchaultG2005The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patientsPulm Pharmacol Ther18495415607127
   PubMed Web of Science ®Google Scholar
• OwenCA2005Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary diseaseProc Am Thorac Soc23738516267366
   PubMedGoogle Scholar
• PalfreymanMNSounessJE1996Phosphodiesterase type IV inhibitorsProg Med Chem331528776940
   PubMedGoogle Scholar
• PalfreymanMN1995Phosphodiesterase type IV inhibitors as antiinflammatory agentsDrugs Fut20793804
   Google Scholar
• PaninaPMarianiMD’AmbrosioD2006Chemokine receptors in chronic obstructive pulmonary disease (COPD)Curr Drug Targets76697416787169
   PubMed Web of Science ®Google Scholar
• PauwelsR2002Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass?Am J Respir Crit Care Med16515798012070055
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPM2001Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Resp Crit Care Med16312567611316667
   PubMedGoogle Scholar
• PerssonCGErjefaltIGustafssonB1988Xanthines-symptomatic or prophylactic in asthma?Agents ActionsSuppl 23137553261498
   PubMedGoogle Scholar
• PerssonCGA1986Overview of effects of theophyllineJ Allergy Clin Immunol7878072877016
   PubMed Web of Science ®Google Scholar
• PettyTL1998Supportive therapy in COPDChest113Suppl256S262S9552015
   PubMed Web of Science ®Google Scholar
• PintoILBuckleDRReadshawSA1993The selective inhibition of phosphate phosphodiesterase from vascular smooth muscle by rolipram analoguesBioorg Med Chem Lett317436
   Web of Science ®Google Scholar
• PolkeyMIMoxhamJ2006Attacking the disease spiral in chronic obstructive pulmonary diseaseClin Med6190616688981
   PubMed Web of Science ®Google Scholar
• PoolePJBlackPN2006Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary diseaseCochrane Database Syst Rev19CD001287
   Google Scholar
• ProfitaMChiapparaGMirabellaF2003Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPDThorax58573912832668
   PubMed Web of Science ®Google Scholar
• RabeKFBatemanEDO’DonnellD2005Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trialLancet3665637116099292
   PubMed Web of Science ®Google Scholar
• RabeKFMagnussenHDentG1995Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxantsEur Resp J863742
   PubMed Web of Science ®Google Scholar
• RabeKF2006Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategiesProc Am Thorac Soc3270516636097
   PubMedGoogle Scholar
• RahmanIAdcockIM2006Oxidative stress and redox regulation of lung inflammation in COPDEur Respir J282194216816350
   PubMed Web of Science ®Google Scholar
• RahmanIKiltyI2006Antioxidant therapeutic targets in COPDCurr Drug Targets77072016787173
   PubMed Web of Science ®Google Scholar
• RamFSJonesPWCastroAA2002Oral theophylline for chronic obstructive pulmonary diseaseCochrane Database Syst Rev4CD00390212519617
   PubMedGoogle Scholar
• RamFSRodriguez-RoisinRGranados-NavarreteA2006Antibiotics for exacerbations of chronic obstructive pulmonary diseaseCochrane Database Syst Rev19CD004403
   Google Scholar
• ReidP2002Roflumilast Altana PharmaCurr Opin Investig Drugs3116570
   PubMedGoogle Scholar
• RenauTE2004The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challengesCurr Opin Investig Drugs5349
   PubMedGoogle Scholar
• RiccioniGDi IlioCContiP2004Advances in therapy with antileukotriene drugsAnn Clin Lab Sci343798715648777
   PubMed Web of Science ®Google Scholar
• RichmondRZwarN2003Review of bupropion for smoking cessationDrug Alcohol Rev222032012850907
   PubMed Web of Science ®Google Scholar
• RobichaudAStamatiouPBJinC2002Deletion of phosphodiesterase 4D in mice shortens alpha2-adrenoceptor-mediated anesthesia, a behavioural correlate of emesisJ Clin Invest11010455212370283
   PubMed Web of Science ®Google Scholar
• Rodriguez-RoisinR2006COPD exacerbations. 5: managementThorax615354416738044
   PubMed Web of Science ®Google Scholar
• RogersDFBarnesPJ2006Treatment of airway mucus hypersecretionAnn Med381162516581697
   PubMed Web of Science ®Google Scholar
• RogersDFGiembyczMA1998Conquering airway inflammation in the 21st centuryDrug Disc Today35325
   Web of Science ®Google Scholar
• RomanoSJ2005Selectin antagonists: therapeutic potential in asthma and COPDTreat Respir Med4859415813660
   PubMedGoogle Scholar
• SadowskaAMKlebeBGermonpreP2006Glucocorticosteroids as antioxidants in treatment of asthma and COPD. New application for an old medication?Steroids721617145070
   PubMed Web of Science ®Google Scholar
• SaettaMDi StefanoATuratoG1998CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med15782269517597
   PubMed Web of Science ®Google Scholar
• SaintSBentSVittinghoffE1995Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysisJAMA273957607884956
   PubMed Web of Science ®Google Scholar
• SanzMJCortijoJMorcilloEJ2005PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expressionPharmacol Ther1062699715922015
   PubMed Web of Science ®Google Scholar
• SasakiMKashimaMItoT2000Differential regulation of metalloproteinases production proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1b and TNFaMediators Inflam915560
   PubMed Web of Science ®Google Scholar
• ScapinGPatelSBChungC2004Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificityBiochem43609110015147193
   PubMed Web of Science ®Google Scholar
• SchmidtBMKusmaMFeuringM2001The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitisJ Allergy Clin Immunol108530611590377
   PubMed Web of Science ®Google Scholar
• SchrammCMGrunsteinMM1992Assessment of signal transduction mechanisms regulating airway smooth muscle contractilityAm J Physiol-Lung Cell Molec Physiol262L11939
   Web of Science ®Google Scholar
• Segura-ValdezLPardoAGaxiolaM2000Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPDChest1176849410712992
   PubMed Web of Science ®Google Scholar
• SeneffMGWagnerDPWagnerRP1995Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary diseaseJAMA274185277500534
   PubMed Web of Science ®Google Scholar
• SeniorRMAnthonisenNR1998Chronic obstructive pulmonary disease (COPD)Am J Resp Crit Care Med15713947
   Web of Science ®Google Scholar
• SiafakasNMTzortzakiEG2002Few smokers develop COPD. Why?Respir Med966152412195843
   PubMed Web of Science ®Google Scholar
• SilverPJHamelLTPerroneMH1988Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscleEur J Pharmacol15085942841146
   PubMed Web of Science ®Google Scholar
• SinDDJohnsonMGanWQ2004Combination therapy of inhaled corticosteroids and long-acting beta2-adrenergics in management of patients with chronic obstructive pulmonary diseaseCurr Pharm Des1035476015579052
   PubMed Web of Science ®Google Scholar
• SinDDMcAlisterFAManSF2003Contemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA29023011214600189
   PubMed Web of Science ®Google Scholar
• SlimRMSongYAlbassamM2003Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in ratsToxicol Pathol316384514585732
   PubMed Web of Science ®Google Scholar
• SoderlingSHBeavoJA2000Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functionsCurr Opin Cell Biol12174910712916
   PubMed Web of Science ®Google Scholar
• SotoFJHananiaNA2005Selective phosphodiesterase-4 inhibitors in chronic obstructive lung diseaseCurr Opin Pulmon Med1112934
   PubMed Web of Science ®Google Scholar
• SounessJEGriffinMMaslenC1996Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformerBr J Pharmacol118649588762090
   PubMed Web of Science ®Google Scholar
• SounessJEHoughtonCSardarN1997Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformerBr J Pharmacol121743509208143
   PubMed Web of Science ®Google Scholar
• SounessJERaoS1997Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterasesCell Signalling9227369218122
   PubMed Web of Science ®Google Scholar
• SpinaD2000The potential of PDE4 inhibitors in asthma or COPDCurr Opin Investig Drugs120413
   PubMedGoogle Scholar
• SpinaD2003Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung diseaseDrugs6325759414636078
   PubMed Web of Science ®Google Scholar
• SpinaD2004The potential of PDE4 inhibitors in respiratory diseaseCurr Drug Targets Inflamm Allergy3231615379590
   PubMedGoogle Scholar
• SpondJCaseNChapmanRW2003Inhibition of experimental acute pulmonary inflammation by pirfenidonePulm Pharmacol Ther162071412850123
   PubMed Web of Science ®Google Scholar
• StockleyRA2002Neutrophils and the pathogenesis of COPDChest1215Suppl 151S155S
   Google Scholar
• SullivanPBekirSJaffarZ1994Anti-inflammatory effects of low-dose oral theophylline in atopic asthmaLancet343100687909049
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
   PubMed Web of Science ®Google Scholar
• TaylorDR1998Chronic obstructive pulmonary disease; no longer any justification for therapeutic nihilismBr Med J3167143
   Web of Science ®Google Scholar
• TeixeiraMMGristwoodRWCooperN1997Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?Trends Pharmacol Sci18164709184477
   PubMed Web of Science ®Google Scholar
• ThompsonWJ1991Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and functionPharmacol Ther5113331663250
   PubMed Web of Science ®Google Scholar
• TimmerWLeclercVBirrauxG2002The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivoJ Clin Pharmacol4229730311865966
   PubMed Web of Science ®Google Scholar
• TorphyTJBarnetteMSUnderwoodDC1999Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinicPulmon Pharmacol Ther121315
   PubMed Web of Science ®Google Scholar
• TorphyTJPageC2000Phosphodiesterases: the journey towards therapeuticsTrends Pharmacol Sci21157910885973
   PubMedGoogle Scholar
• TorphyTJStadelJMBurmanM1992Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeastJ Biol Chem26717988041309798
   PubMed Web of Science ®Google Scholar
• TorphyTJUndemBJ1991Phosphodiesterase inhibitors: new opportunities for the treatment of asthmaThorax46512231877039
   PubMed Web of Science ®Google Scholar
• TorphyTJ1994Beta-Adrenoceptors, cAMP and airway smooth muscle: challenges to the dogmaTrends Pharmacol Sci1537047809952
   PubMed Web of Science ®Google Scholar
• TorphyTJ1998Phosphodiesterase isozymes: molecular targets for novel antiasthma agentsAm J Resp Crit Care Med157351709476844
   PubMed Web of Science ®Google Scholar
• TrifilieffAKellerTHPressNJ2005CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activitiesBr J Pharmacol14410021015685201
   PubMed Web of Science ®Google Scholar
• UndemBJMeekerSNChenJ1994Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitorsJ Pharmacol Exp Ther271811177965800
   PubMed Web of Science ®Google Scholar
• UnderwoodDCBochnowizSOsbornRR1998Antiasthmatic activity of the second generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigJ Pharmacol Exp Ther287988959864284
   PubMed Web of Science ®Google Scholar
• UnderwoodDCKotzerCJBochnowiczS1994Comparison of phosphodiesterase III, IV, and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigsJ Pharmacol Exp Ther27025098035322
   PubMed Web of Science ®Google Scholar
• van SchalkwykEStrydomKWilliamsZ2005Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactionsJ Allergy Clin Immunol116292816083782
   PubMed Web of Science ®Google Scholar
• van SchayckCPReidJ2006Effective management of COPD in primary care – the role of long-acting beta agonist/inhaled corticosteroid combination therapyPrim Care Respir J151435116757394
   PubMedGoogle Scholar
• VassalloRLipskyJJ1998Theophylline: recent advances in the understanding of its mode of action and uses in clinical practiceMayo Clinic Proc7334654
   PubMed Web of Science ®Google Scholar
• VeeramachaneniSBSethiS2006Pathogenesis of bacterial exacerbations of COPDCOPD31091517175674
   PubMedGoogle Scholar
• VignolaAM2004PDE4 inhibitors in COPD-a more selective approach to treatmentRespir Med9849550315191033
   PubMed Web of Science ®Google Scholar
• WangPWuPOhlethKM1999Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophilsMol Pharmacol56170410385698
   PubMed Web of Science ®Google Scholar
• WeinbergerMHendelesL1996Theophylline in asthmaN Engl J Med334138088614425
   PubMed Web of Science ®Google Scholar
• WeinbergerM1988Treatment of chronic asthma with theophyllineISI Atlas Sci Pharmacol25361
   Google Scholar
• WongMLWhelanFDeloukasP2006Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment responseProc Natl Acad Sci USA103151242917008408
   PubMed Web of Science ®Google Scholar
• WrightJLChurgA2006Advances in the pathology of COPDHistopathol4919
   PubMed Web of Science ®Google Scholar
• ZaherCHalbertRDuboisR2004Smoking-related diseases: the importance of COPDIntl J Tuberculosis Lung Dis814238
   PubMed Web of Science ®Google Scholar
• ZhuYKLiuXDSkoldCM2001Synergistic neutrophil elastasecytokine interaction degrades collagen in three-dimensional cultureAm J Physiol Lung Cell Mol Physiol281L8687811557590
   PubMed Web of Science ®Google Scholar